Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;103:415-422

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ruehm, S. G.
Right arrow Articles by Debatin, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruehm, S. G.
Right arrow Articles by Debatin, J. F.
Related Collections
Right arrow Cardiovascular imaging agents/Techniques
Right arrow Imaging
Right arrow CT and MRI

(Circulation. 2001;103:415.)
© 2001 American Heart Association, Inc.


Basic Science Reports

Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic Rabbits

Stefan G. Ruehm, MD; Claire Corot, PhD; Peter Vogt, MD; Stefan Kolb, MD; Jörg F. Debatin, MD

From the Institutes of Diagnostic Radiology (S.G.R., J.F.D.) and Pathology (P.V., S.K.), University Hospital Zürich, Switzerland, and the Laboratoire Guerbet, Aulnay Sous Bois, France (C.C.). Drs Ruehm and Debatin are now at the Department of Diagnostic Radiology, University Hospital Essen, Germany.

Correspondence to Jörg F. Debatin, MD, Department of Diagnostic Radiology, University Hospital Essen, Hufelandstraße 55, D-45122 Essen, Germany. E-mail debatin{at}uni-essen.de


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background—Based on the observation that ultrasmall superparamagnetic particles of iron oxides (USPIOs) are phagocytosed by cells of the mononuclear phagocytic system, the purpose of this study was to evaluate their use as a marker of atherosclerosis-associated inflammatory changes in the vessel wall before luminal narrowing is present.

Methods and Results—Experiments were conducted on 6 heritable hyperlipidemic and 3 New Zealand White rabbits. 3D MR angiography (MRA) of the thoracic aorta was performed on all rabbits by use of a conventional paramagnetic contrast agent that failed to reveal any abnormalities. One week later, all rabbits except 1 of the hyperlipidemic animals were injected with a USPIO contrast agent (Sinerem, Guerbet) at a dose of 1 mmol Fe/kg. 3D MRA data sets collected over the subsequent 5 days showed increasing signal in the aortic lumen. Whereas the aortic wall of the control rabbits remained smooth and bright, marked susceptibility effects became evident on day 4 within the aortic walls of hyperlipidemic rabbits. Ex vivo imaging of aortic specimens confirmed the in vivo results. Histopathology documented marked Fe uptake in macrophages embedded in atherosclerotic plaque of the hyperlipidemic rabbits. Electron microscopy showed multiple cytoplasmic Fe particles in macrophages. No such changes were seen in control rabbits or in the hyperlipidemic rabbit that had not received Sinerem.

Conclusions—USPIOs are phagocytosed by macrophages in atherosclerotic plaques of the aortic wall of hyperlipidemic rabbits in a quantity sufficient to cause susceptibility effects detectable by MRI.


Key Words: atherosclerosis • magnetic resonance imaging • plaque • contrast media


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Atherosclerosis represents a chronic inflammatory response to vessel wall injury, ending in an acute event induced by plaque rupture. Various injurious agents affecting the vessel walls cause an excessive inflammatory-fibroproliferative response resulting in progressive atherosclerotic plaque formation.1 2 3 Because the risks for thrombosis are more dependent on the particular plaque configuration than on the degree of luminal narrowing,4 the radiological assessment of atherosclerosis should extend beyond the mere depiction of luminal narrowing.

The uptake of intravenously administered superparamagnetic iron oxide preparations into cells of the mononuclear phagocytic system (MPS) results in hepatic, splenic, bone marrow, and nodal iron accumulation. Exploiting iron-associated T2 and T2* shortening effects, the select accumulation of iron particles in the MPS system has been successfully used for organ-specific MRI.5 6 7 In contrast to superparamagnetic iron oxide preparations composed of large particles (mean particle diameter, 72 nm) or magnetite albumin microspheres (mean particle diameter, 1 to 5 µm), ultrasmall particles of iron oxide (USPIOs) (mean diameter, 18 nm) are not immediately recognized by the hepatic and splenic MPS.8 9 The resulting prolongation of the intravascular half-life, together with inherent T1 shortening properties, has allowed USPIOs to be used as MR angiography (MRA) blood pool agents.10 In contrast to the large-particle superparamagnetic agents, the small USPIOs can extravasate through tight capillary pores characterized by diameters ranging between 5 and 100 nm.11 This capillary permeability permits USPIO uptake in MPS cells throughout the body.

Ross3 described the various stages of atherosclerotic genesis to represent different stages in a chronic inflammatory process affecting the arterial wall. The earliest lesion, the so-called "fatty streak," can be found even in children12 and represents a primitive inflammatory response consisting of monocyte-derived macrophages and T lymphocytes.13 Because MPS cells are present in the atherosclerotic vessel wall, ultrasmall particulate iron oxide agents capable of navigating the very tight interstitial endothelial pores might be used to detect early atherosclerotic changes on MR images by means of USPIO-associated T2 and T2* shortening effects.

The purpose of this study was to evaluate the performance of USPIOs as a marker of macrophage activity in early atherosclerotic changes in the aortic wall of hyperlipidemic rabbits.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Experiments were conducted on 6 heritable hyperlipidemic rabbits (Harlan Interfauna Ltd, Wyton, Huntingdon Cambs, UK), a modified strain of Watanabe heritable hyperlipidemic (WHHL) rabbits, and 3 New Zealand White rabbits that served as a control group. The animals were 6 to 10 months of age. At this age, the animals are known to harbor active plaque formations within the aortic wall.14 All experiments were performed in full accordance with all regulations governing animal studies.

For each MRI session, the rabbits were fully anesthetized with ketamine (Ketasol 100, Dr. E. Graeub AG) 0.6 mL/kg body wt and xylazine (Rompun 2%, Bayer) 0.2 mL/kg body wt. All MRI was performed on a 1.5-T system (Signa Echospeed, GEMS). To maximize signal-to-noise ratio (SNR), a quadrature transmit-receive head coil was used. For 3D MRA, a 3D-enhanced fast gradient recall echo data set similar to that used for conventional 3D MRA was collected in the coronal plane with the following parameters: TR, 6.7 ms; TE, 1.6 ms; flip angle, 30°. A field of view of 28x19.6 cm was combined with a 256x192 matrix to provide an in-plane resolution of 1.1x1.0 mm. Two excitations were averaged. Thirty-two contiguous sections 1.4 mm thick were collected over 82 seconds. The use of zero interpolation in all 3 planes reduced voxel spacing by a factor of 2.

Experimental Design
The experiments were stacked to include 3D MRA imaging after the administration of conventional extracellular as well as USPIO contrast agents. Although 5 hyperlipidemic and all 3 control rabbits underwent the entire experimental protocol, 1 hyperlipidemic rabbit was not injected with the USPIO agent, thus skipping the second step of the outlined protocol:

1. Conventional 3D contrast-enhanced MRA of the thoracic aorta using conventional extracellular paramagnetic contrast material. During the acquisition of the 3D data set, 2 mL Gd-DOTA (Dotarem, Laboratoire Guerbet) diluted in 10 mL saline was injected intravenously by an automated injector at a flow rate of 0.1 mL/s.

2. After a 1-week delay to ensure excretion of all extracellular contrast material, the USPIO contrast agent (Sinerem, Laboratoire Guerbet) was injected intravenously at a dose of 1 mmol Fe/kg. 3D MRA imaging was performed daily up to 5 days after the intravenous Sinerem application.

3. After the 3D MRA imaging session on day 5, the rabbits were euthanized and the aortic specimen was removed. For ex vivo imaging, the aorta was tied at both ends, and the lumen was filled with water spiked with Gd-DOTA (1:50 dilution) to simulate the effect of intravascular contrast. The aortic specimens were placed in a small plastic container filled with saline for 3D MRA imaging.

4. Finally, the aortic specimen was subjected to histopathological evaluation. The vessel walls were inspected grossly for plaque protruding into the vessel lumen and subsequently scanned for the presence of iron after histochemical staining (Prussian blue staining). For electron microscopic analysis, a small portion of aortic wall of 2 hyperlipidemic rabbits was subsequently sampled: 1 that had received Sinerem and the 1 that had not.

Image Analysis
MRA data sets were postprocessed (Advantage Windows, GEMS). Maximum intensity projections (MIPs) were rendered. Rotated MIP displays ranging from -60° to +60° were documented on film. In addition, source images were available for analysis on a workstation, which also allowed for interactive multiplanar reformatting of the data sets.

3D MRA data sets were analyzed by an observer blinded to the type of contrast agent administered as well as the type of animal regarding the ability to identify iron-induced susceptibility effects within the aortic wall.

For quantitative analysis, signal intensities were measured within regions of interest (ROIs) placed within the aortic lumen as well as within the aortic wall just beyond the confines of the vessel lumen. SNRs were calculated. To this end, individual source images were magnified on a workstation (Advantage Windows). SNR measurements were performed in a single larger ROI (9 mm2) placed within the aortic lumen and 3 small (1.1 mm2) ROIs placed within the aortic wall, demonstrating marked USPIO uptake (hyperlipidemic rabbits) and corresponding regions in normal control rabbits. Measurements were performed on the precontrast image set as well as on the images collected on days 1, 2, 3, 4, and 5 after administration of Sinerem. Care was taken to ensure that ROIs of identical size were placed in identical locations on the different images. To compare the enhancement pattern and thus the uptake of USPIO in the aortic wall between hyperlipidemic rabbits and normal control rabbits, a paired t test was performed on data points obtained on the precontrast images and those based on the day 5 post-Sinerem images.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
3D MRA in conjunction with the conventional extracellular contrast agent Gd-DOTA failed to reveal any abnormality in either the hyperlipidemic or control rabbits. The aortic lumen was homogeneously bright, permitting easy assessment of the aortic lumen. The aortic wall appeared smooth, without any evidence of atherosclerotic plaque formations (Figure 1Down).



View larger version (144K):
[in this window]
[in a new window]
 
Figure 1. A, Coronal MIP and (B) sagittal oblique and (C) coronal oblique reformatted images of contrast-enhanced 3D MRA data set collected after intravenous administration of Gd-DOTA displaying aorta of 7-month-old hyperlipidemic rabbit. Aortic wall is smooth, without evidence of luminal narrowing.

After the administration of USPIO, intravascular signal intensities were dramatically decreased. Reflecting a decrease of T2* effects induced by decreasing intravascular USPIO concentrations, luminal signal steadily increased over the 5-day imaging period, providing the best angiographic effect on day 5 for hyperlipidemic and control rabbits alike (Figures 2ADown and 3Down). Because of extensive susceptibility effects, delineation of the aortic wall and thus placement of ROIs were not reliably possible in any of the animals on the first 2 days after Sinerem administration. On day 3, visual inspection permitted delineation of the aortic wall in 2 of 5 hyperlipidemic and 1 of 3 normal control animals. On days 4 and 5 after contrast administration, the wall could be delineated in all animals. In the 3 control rabbits, the aortic wall was found to be smooth, void of any irregularities. The data sets obtained in the hyperlipidemic rabbits, conversely, began to exhibit irregularities first seen in 2 animals on day 3 and the remaining 3 rabbits on day 4. These irregularities, appearing as spotty signal voids, became more pronounced on day 5 and reflect susceptibility effects from iron deposits within the aortic wall (Figure 3Down).



View larger version (17K):
[in this window]
[in a new window]
 
Figure 2. SNR measurements obtained in ROI in aortic lumen and wall of hyperlipidemic (n=5) and control rabbits (n=3) after intravenous administration of USPIO contrast agent Sinerem at a dose of 1 mmol Fe/kg. A, Intraluminal signal measured in single large ROI (9 mm2) revealed significant increase in SNR, with maximum reached at day 5 after contrast administration. These changes reflect T2* effects, which decreased over time. B, SNR values based on 3 ROI measurements in aortic wall of each animal failed to reveal statistical difference between precontrast and 5 days post-Sinerem image sets in normal control rabbits. In hyperlipidemic animals, conversely, significant decrease in SNR corresponding to select USPIO uptake in plaque formations containing MPS cells was evident.



View larger version (110K):
[in this window]
[in a new window]
 
Figure 3. A, Coronal MIP and (B) sagittal oblique and (C) coronal oblique reformatted images of contrast-enhanced 3D MRA data sets of same hyperlipidemic rabbit as depicted in Figure 1Up obtained 5 days after intravenous injection of USPIO agent Sinerem. Note susceptibility effects originating within vessel wall and representing Fe uptake in macrophages embedded in plaque.

Quantitative analysis based on SNR measurements of the vessel lumen confirmed the visual impression: Intraluminal signal measured in a single large ROI revealed a significant increase in SNR, with a maximum reached at day 5 after contrast administration. These changes reflect T2* effects, which decreased over time (Figure 2AUp). Similarly, the qualitative assessment of the aortic wall is mirrored by the quantitative analysis: although there was no significant difference in SNR values between the precontrast and 5 days postcontrast image sets obtained in normal control rabbits (P>0.05; paired t test), a vast difference was evident in the hyperlipidemic rabbits (P<0.01; paired t test) (Figure 2BUp). Thus, USPIO uptake was evident only in the aortic wall of hyperlipidemic rabbits.

The ex vivo data sets were very similar in appearance to the images collected in vivo on day 5 immediately before the rabbits were euthanized (Figure 4Down). Gross inspection of the aortic walls of hyperlipidemic as well as control rabbits did not reveal any appreciable irregularities. Histopathological analysis showed marked uptake of Fe particles in macrophages embedded in atherosclerotic plaque found in the aortic wall of all 5 hyperlipidemic rabbits that had received USPIOs (Figure 5Down). No such changes were seen in the control rabbits. In the 1 hyperlipidemic rabbit killed without having received USPIOs, plaque was identified without evidence of iron uptake.



View larger version (141K):
[in this window]
[in a new window]
 
Figure 4. Ex vivo imaging of contrast-filled aortic specimen of (A) hyperlipidemic rabbit 5 days after administration of Sinerem, (B) normal control rabbit 5 days after administration of Sinerem, and (C) hyperlipidemic rabbit that did not receive Sinerem. Marked susceptibility artifacts are present in aortic wall of hyperlipidemic rabbit that had received Sinerem (A). No such changes are visualized in other 2 rabbits (B, C).



View larger version (132K):
[in this window]
[in a new window]
 
Figure 5. Cross-sectional histopathological sections with Prussian blue staining of aorta of same hyperlipidemic rabbit as depicted in Figures 1Up and 3Up, killed 5 days after administration of USPIO agent Sinerem. Note thickening of intima with marked staining of Fe particles embedded in atherosclerotic plaque formations.

Electron microscopy (Figures 6Down and 7Down) demonstrated multiple foam cells containing an abundance of fatty vacuoles in a thickened subendothelial layer of the aortic wall of the 2 hyperlipidemic rabbits. However, only the atherosclerotic rabbit that received Sinerem showed multiple cytoplasmic Fe particles (Figure 6Down).



View larger version (105K):
[in this window]
[in a new window]
 
Figure 6. Electron microscopy of aorta of hyperlipidemic rabbit 5 days after administration of Sinerem. Active macrophages derived from smooth muscle cells reveal cytoplasmic inclusion of Fe particles. Surrounding foam cells with multiple fatty vacuoles lack any Fe uptake. Magnification: A, x1150; B, x5400.



View larger version (116K):
[in this window]
[in a new window]
 
Figure 7. Electron microscopy of aortic wall from hyperlipidemic rabbit that had not received Sinerem. Atherosclerotic changes with abundance of foam cells are similar to those seen in Figure 6Up. There is, however, no Fe uptake in MPS cells. Magnification: A, x810; B, x1150.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The results of this preliminary animal study indicate that indeed, USPIOs are phagocytosed by MPS cells contained within atherosclerotic plaque in a quantity sufficient to be detected on T1-weighted 3D GRE images as susceptibility-induced signal voids. The implications of this observation are potentially vast, because they may profoundly affect future strategies for the diagnosis and therapy of atherosclerotic disease.15

Already today, MRI techniques are widely used for assessing the vascular system. Featuring noninvasiveness, contrast agents without nephrotoxicity, and 3-dimensionality, contrast-enhanced 3D MRA is rapidly replacing conventional catheter angiography as the primary means for evaluating the arterial system.16 17 The technique is based on the same luminographic approach that has dominated diagnostic and therapeutic strategies for atherosclerotic disease over the past decades.18 The data presented underscore the limitations inherent to luminography: contrast-enhanced 3D MRA with conventional extracellular Gd-based contrast failed to identify plaque formation in the hyperlipidemic animals examined (Figure 1Up). Similar observations have been reported by other groups using digital subtraction angiography, which failed to detect wall abnormalities in hyperlipidemic rabbits 6 to 12 months old, although alternative imaging with high-resolution MRI14 and endovascular ultrasound19 confirmed extensive thickening of the aortic wall.

Recognizing the need to shift emphasis from the vascular lumen to the arterial wall, high-resolution MRI has been increasingly considered for assessing the vascular system. Reflecting the unsurpassed soft tissue contrast inherent to the MR experiment, MR images were found to be superior to intravascular ultrasound with regard to plaque characterization.20 MR-based visualization of the vascular wall does, however, require high spatial resolution. To achieve this, both external and intravascular surface coils were used. Limited signal and depth penetration allowed wall imaging with external coils only of peripheral vessels, such as the carotid,21 femoral, or popliteal arteries. Although intravascular coils can overcome this limitation,22 23 24 25 providing sufficient spatial resolution (117x156 µm) even to permit characterization of different plaque components,14 they do mandate an invasive approach.

The proposed USPIO method pursues a totally different approach. Instead of defining the morphological makeup of atherosclerotic plaque, a functional strategy is pursued. Based on the assumption that regions of active plaque formation harbor phagocytic cells, the technique is based on the intravenous administration of ultrasmall iron particles with a long intravascular half-life. If we rely on the susceptibility effects associated with the accumulation of superparamagnetic iron particles (T2* effect), rather small amounts of iron are sufficient to induce vast changes on susceptibility-sensitive gradient echo MR images (Figure 3Up). The signal changes induced by the iron in the aortic plaque deposits were found to be statistically significant (P<0.05).

The USPIO agent Sinerem has been designed for clinical lymph node imaging.6 9 It has successfully completed phase 3 clinical testing and has been registered by several health authorities for clinical use. Because of their small size and rather long half-life in the blood, the particles have the capability to migrate through interendothelial junctions and capillary pores with diameters ranging between 5 and 100 nm.11 On the T1-weighted fast 3D GRE sequence used, the USPIO agent is characterized by T1 shortening in lower concentrations, rendering the signal bright, and predominant T2/T2* shortening at higher concentrations, resulting in completely dark signal.26 Thus, the complete signal void in the aortic lumen after initial Sinerem administration reflects the high USPIO blood concentration at this time (Figure 2AUp). After the USPIOs are allowed to be taken up by the MPS over a 4- to 5-day period, an ideal situation for imaging the vascular wall is created: the iron concentration in the inflammatory cells contained within the plaque was sufficiently great for T2 and T2* effects to dominate (Figure 2BUp), whereas the iron concentration in the blood pool had decreased to levels at which the T1 shortening effects dominate (Figure 3Up). This combination of bright intraluminal signal with signal voids contained within the aortic wall permitted identification of regions of active imflammatory changes within the aortic wall at blinded analysis by a single observer at days 4 and 5 after the administration of Sinerem (Figure 3Up). The visual impressions are reflected by the quantitative analysis, which illustrates a dramatic signal decrease in regions of the aortic wall of hyperlipidemic rabbits (Figure 2Up), which at histological analysis corresponded to plaque formations (Figure 5Up).

Electron microscopy confirmed the intracellular presence of the iron particles (Figure 6Up). In addition, on the basis of the presence of myosin filaments, electron microscopy identified macrophages containing cytoplasmic Fe particles to be derivatives from smooth muscle cells (Figure 6Up). These actively phagocytosing cells were surrounded by inactive foam cells filled with fat vacuoles without cytoplasmic iron (Figures 6Up and 7Up). These observations lend support to more recent reports favoring endothelial dysfunction rather than the response-to-injury hypothesis, with endothelial denudation representing the first step of atherosclerosis.27 Regardless of the cause, atherosclerosis represents an inflammatory process.3 Although the early fatty streak is made up of primitive macrophages and T lymphoctes,13 continued inflammation causes activation of more macrophages and lymphocytes, with release of hydrolytic enzymes, cytokines, and growth factors leading to necrosis.28 Further accumulation of mononuclear cells coupled with proliferation of smooth muscle cells and formation of fibrous tissue results in plaque growth. Further restructuring can lead to a so-called fibrous cap covering a core of lipid and necrotic tissue. This advanced stage is regarded as a complicated plaque lesion.3

Because USPIO accumulation appears to directly reflect the presence of inflammation, it stands to reason that iron accumulation will occur only in plaque, subject to an active inflammatory reaction. On the assumption that the presence of MPS cells indicates the presence of active plaque, USPIOs may thus serve as a marker of active atherosclerotic plaque formation at a time long before luminal narrowing becomes evident. The technique therefore may not only detect atherosclerotic disease during the often lengthy preclinical phase, which may last decades,29 but instead should also aid in gauging the activity and thus the clinical relevance of older plaques. Because this study did not determine the physiological state of plaque, however, this conjecture, although likely, remains unproven. Further work will be directed at classifying plaque with high-resolution MRI and correlating the morphology of these formations with USPIO uptake.

Clearly, this animal study has limitations. The number of rabbits examined is small. To overcome this limitation, the study design encompassed examinations of 3 control rabbits as well as of 1 hyperlipidemic rabbit that did not receive the USPIO agent. The results leave little doubt as to the reproducibility of the observed changes affecting the aortic wall. A more severe limitation is associated with the fact that the rabbits were injected with {approx}10 times the permitted clinical dose. Although it is quite possible that a reduced dose would produce the same effects, a dose-finding study has not yet been performed. Similarly, the imaging sequence has not been optimized: the sensitivity for iron-induced susceptibility effects could be enhanced by use of a more T2*-weighted GRE sequence with longer echo times. With such a sequence, even smaller accumulations of iron could be detected, thereby potentially reducing the required contrast dose. Finally, although several characteristics supported the choice of the heritable hyperlipidemic rabbit as a model for this study, the observed imaging effects may be particular to this animal model. The documented similarity between rabbit and human atherosclerotic plaque formation30 31 32 33 makes this an unlikely scenario, however.

We conclude that the intravenous administration of USPIOs permits delineation of inflammatory changes accompanying the atherosclerotic disease process in hyperlipidemic rabbits. The medical, social, and economic potential associated with early detection and characterization of plaque activity warrants further investigation.

Received June 14, 2000; revision received July 20, 2000; accepted July 31, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]

2. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995;91:2488–2496.[Abstract/Free Full Text]

3. Ross R, Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126.[Free Full Text]

4. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes, I. N Engl J Med. 1992;326:242–250.[Medline] [Order article via Infotrieve]

5. Saini S, Stark DD, Hahn PF, et al. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology. 1987;162:211–216.[Abstract/Free Full Text]

6. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology. 1990;175:494–498.[Abstract/Free Full Text]

7. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol. 1989;152:167–173.[Abstract/Free Full Text]

8. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology. 1990;175:489–493.[Abstract/Free Full Text]

9. Vassallo P, Matei C, Heston WD, et al. AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes. Radiology. 1994;193:501–506.[Abstract/Free Full Text]

10. Anzai Y, Prince MR, Chenevert TL, et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging.. 1997;7:209–214.[Medline] [Order article via Infotrieve]

11. Renkin EM. Multiple pathways of capillary permeability. Circ Res. 1977;41:735–743.[Abstract/Free Full Text]

12. Napoli C, D’Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680–2690.[Medline] [Order article via Infotrieve]

13. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462–2478.[Abstract/Free Full Text]

14. Zimmermann-Paul GG, Quick HH, Vogt P, et al. High-resolution intravascular magnetic resonance imaging: monitoring of plaque formation in heritable hyperlipidemic rabbits. Circulation. 1999;99:1054–1061.[Abstract/Free Full Text]

15. Celermajer DS. Noninvasive detection of atherosclerosis. N Engl J Med. 1998;339:2014–2015.[Free Full Text]

16. Prince MR, Narasimham DL, Stanley JC, et al. Breath-hold gadolinium-enhanced MR angiography of the abdominal aorta and its major branches. Radiology. 1995;197:785–792.[Abstract/Free Full Text]

17. Snidow JJ, Aisen AM, Harris VJ, et al. Iliac artery MR angiography: comparison of three-dimensional gadolinium-enhanced and two-dimensional time-of-flight techniques. Radiology. 1995;196:371–378.[Abstract/Free Full Text]

18. Prince MR. Gadolinium-enhanced MR aortography. Radiology. 1994;191:155–164.[Abstract/Free Full Text]

19. Hong MK, Leon MB, Mintz GS. Usefulness of intravascular ultrasound for detecting atherosclerosis progression or regression. In: Lloyd W. Klein, ed. Coronary Stenosis Morphology: Analysis and Implication. Boston, Mass: Kluwer Academic Publishers; 1997:239–250.

20. Martin A, Ryan L, Gottlieb A, et al. Arterial imaging: comparison of high-resolution US and MR imaging with histologic correlation. Radiographics. 1997;17:189–202.[Abstract]

21. Toussaint JF, LaMuraglia GM, Southern JF, et al. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation. 1996;94:932–938.[Abstract/Free Full Text]

22. Atalar E, Bottomley PA, Ocali O, et al. High resolution intravascular MRI and MRS by using a catheter receiver coil. Magn Reson Med. 1996;36:596–605.[Medline] [Order article via Infotrieve]

23. Kandarpa K, Chopra PS, Aruny JE, et al. Intraarterial thrombolysis of lower extremity occlusions: prospective, randomized comparison of forced periodic infusion and conventional slow continuous infusion [see comments]. Radiology. 1993;188:861–867.[Abstract/Free Full Text]

24. Martin A, Plewes D, Henkelmann R. MR imaging of blood vessels with an intravascular coil. J Magn Reson Imaging. 1992;2:421–429.[Medline] [Order article via Infotrieve]

25. Hurst G, Hua J, Duerk J, Cohen A. Intravascular (catheter) NMR receiver probe: preliminary design analysis and application to canine iliofemoral imaging. Magn Reson Med. 1992;24:343–357.[Medline] [Order article via Infotrieve]

26. Rozenman Y, Zou X, Kantor H. Signal loss induced by superparamagnetic iron oxide particles in NMR spin-echo images: the role of diffusion. Magn Reson Med. 1990;14:31–39.[Medline] [Order article via Infotrieve]

27. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973;180:1332–1339.[Free Full Text]

28. Libby P, Ross R. Cytokines and growth regulatory molecules. In: Fuster V, Ross R, Topol E, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott-Raven; 1996:585–594.

29. Hozumi T, Yoshida K, Ogata Y, et al. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation. 1998;97:1557–1562.[Abstract/Free Full Text]

30. Esper E, Chan EK, Buchwald H. Natural history of atherosclerosis and hyperlipidemia in heterozygous WHHL (WHHL-Hh) rabbits, I: the effects of aging and gender on plasma lipids and lipoproteins. J Lab Clin Med. 1993;121:97–102.[Medline] [Order article via Infotrieve]

31. Esper E, Runge WJ, Gunther R, et al. Natural history of atherosclerosis and hyperlipidemia in heterozygous WHHL (WHHL-Hh) rabbits, II: morphologic evaluation of spontaneously occurring aortic and coronary lesions. J Lab Clin Med. 1993;121:103–110.[Medline] [Order article via Infotrieve]

32. Donnelly TM, Kelsey SF, Levine DM, et al. Control of variance in experimental studies of hyperlipidemia using the WHHL rabbit. J Lipid Res. 1991;32:1089–1098.[Abstract]

33. Atkinson JB, Hoover RL, Berry KK, et al. Cholesterol-fed heterozygous Watanabe heritable hyperlipidemic rabbits: a new model for atherosclerosis. Atherosclerosis. 1989;78:123–136.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. R. Olzinski, G. H. Turner, R. E. Bernard, H. Karr, C. A. Cornejo, K. Aravindhan, B. Hoang, M. A. Ringenberg, P. Qin, K. B. Goodman, et al.
Pharmacological Inhibition of C-C Chemokine Receptor 2 Decreases Macrophage Infiltration in the Aortic Root of the Human C-C Chemokine Receptor 2/Apolipoprotein E-/- Mouse: Magnetic Resonance Imaging Assessment
Arterioscler Thromb Vasc Biol, February 1, 2010; 30(2): 253 - 259.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. M. Matter, M. Stuber, and M. Nahrendorf
Imaging of the unstable plaque: how far have we got?
Eur. Heart J., November 1, 2009; 30(21): 2566 - 2574.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
M. Truijers, J. J. Futterer, S. Takahashi, R. A. Heesakkers, J. D. Blankensteijn, and J. O. Barentsz
In Vivo Imaging of the Aneurysm Wall With MRI and a Macrophage-Specific Contrast Agent
Am. J. Roentgenol., November 1, 2009; 193(5): W437 - W441.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
M. Sigovan, L. Boussel, A. Sulaiman, D. Sappey-Marinier, H. Alsaid, C. Desbleds-Mansard, D. Ibarrola, D. Gamondes, C. Corot, E. Lancelot, et al.
Rapid-Clearance Iron Nanoparticles for Inflammation Imaging of Atherosclerotic Plaque: Initial Experience in Animal Model
Radiology, August 1, 2009; 252(2): 401 - 409.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. P. Cormode, T. Skajaa, Z. A. Fayad, and W. J.M. Mulder
Nanotechnology in Medical Imaging: Probe Design and Applications
Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 992 - 1000.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Y. Tang, K. H. Muller, M. J. Graves, Z. Y. Li, S. R. Walsh, V. Young, U. Sadat, S. P.S. Howarth, and J.H. Gillard
Iron Oxide Particles for Atheroma Imaging
Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1001 - 1008.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. H.F. Rudd, F. Hyafil, and Z. A. Fayad
Inflammation Imaging in Atherosclerosis
Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1009 - 1016.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. L. Kraitchman and J. W.M. Bulte
In Vivo Imaging of Stem Cells and Beta Cells Using Direct Cell Labeling and Reporter Gene Methods
Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1025 - 1030.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Y. Tang, S. P.S. Howarth, S. R. Miller, M. J. Graves, A. J. Patterson, J.-M. U-King-Im, Z. Y. Li, S. R. Walsh, A. P. Brown, P. J. Kirkpatrick, et al.
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study: Evaluation Using Ultrasmall Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging in Carotid Disease
J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2039 - 2050.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol ImgHome page
R. M. Botnar
Coronary Plaque Characterization by T1-Weighted Cardiac Magnetic Resonance
J. Am. Coll. Cardiol. Img., June 1, 2009; 2(6): 729 - 730.
[Full Text] [PDF]


Home page
JNMHome page
F. Hyafil, J.-C. Cornily, J. H.F. Rudd, J. Machac, L. J. Feldman, and Z. A. Fayad
Quantification of Inflammation Within Rabbit Atherosclerotic Plaques Using the Macrophage-Specific CT Contrast Agent N1177: A Comparison with 18F-FDG PET/CT and Histology
J. Nucl. Med., June 1, 2009; 50(6): 959 - 965.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol ImgHome page
T. Ibrahim, M. R. Makowski, A. Jankauskas, D. Maintz, M. Karch, S. Schachoff, W. J. Manning, A. Schomig, M. Schwaiger, and R. M. Botnar
Serial contrast-enhanced cardiac magnetic resonance imaging demonstrates regression of hyperenhancement within the coronary artery wall in patients after acute myocardial infarction.
J. Am. Coll. Cardiol. Img., May 1, 2009; 2(5): 580 - 588.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
A. Elias and A. Tsourkas
Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles
Hematology, January 1, 2009; 2009(1): 720 - 726.
[Abstract] [Full Text] [PDF]


Home page
ESC Textbook of Cardiovascular MedicineHome page
C. A. Nienaber, I. Akin, R. Erbel, and A. Haverich
CHAPTER 31 Diseases of the Aorta and Trauma to the Aorta and the Heart
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
W P Bandettini and A E Arai
Advances in clinical applications of cardiovascular magnetic resonance imaging
Heart, November 1, 2008; 94(11): 1485 - 1495.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
G. Korosoglou, S. Shah, E.-J. Vonken, W. D. Gilson, M. Schar, L. Tang, D. L. Kraitchman, R. C. Boston, D. E. Sosnovik, R. G. Weiss, et al.
Off-Resonance Angiography: A New Method to Depict Vessels--Phantom and Rabbit Studies
Radiology, November 1, 2008; 249(2): 501 - 509.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Korosoglou, R. G. Weiss, D. A. Kedziorek, P. Walczak, W. D. Gilson, M. Schar, D. E. Sosnovik, D. L. Kraitchman, R. C. Boston, J. W.M. Bulte, et al.
Noninvasive Detection of Macrophage-Rich Atherosclerotic Plaque in Hyperlipidemic Rabbits Using "Positive Contrast" Magnetic Resonance Imaging
J. Am. Coll. Cardiol., August 5, 2008; 52(6): 483 - 491.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
G. Bierry, F. Jehl, N. Boehm, P. Robert, G. Prevost, J.-L. Dietemann, H. Desal, and S. Kremer
Macrophage Activity in Infected Areas of an Experimental Vertebral Osteomyelitis Model: USPIO-enhanced MR Imaging--Feasibility Study
Radiology, July 1, 2008; 248(1): 114 - 123.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
W. J.M. Mulder and Z. A. Fayad
Nanomedicine Captures Cardiovascular Disease
Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 801 - 802.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. B. Morris, A. R. Olzinski, R. E. Bernard, K. Aravindhan, R. C. Mirabile, R. Boyce, R. N. Willette, and B. M. Jucker
p38 MAPK Inhibition Reduces Aortic Ultrasmall Superparamagnetic Iron Oxide Uptake in a Mouse Model of Atherosclerosis: MRI Assessment
Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 265 - 271.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Nahrendorf, H. Zhang, S. Hembrador, P. Panizzi, D. E. Sosnovik, E. Aikawa, P. Libby, F. K. Swirski, and R. Weissleder
Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis
Circulation, January 22, 2008; 117(3): 379 - 387.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. F. Kircher, J. Grimm, F. K. Swirski, P. Libby, R. E. Gerszten, J. R. Allport, and R. Weissleder
Noninvasive In Vivo Imaging of Monocyte Trafficking to Atherosclerotic Lesions
Circulation, January 22, 2008; 117(3): 388 - 395.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
T. Y Tang, S. P S Howarth, S. R Miller, M. J Graves, J.-M. U-King-Im, R. A Trivedi, Z. Y. Li, S. R Walsh, A. P Brown, P. J Kirkpatrick, et al.
Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques contralateral to symptomatic carotid stenosis: an ultra small superparamagnetic iron oxide enhanced magnetic resonance study
J. Neurol. Neurosurg. Psychiatry, December 1, 2007; 78(12): 1337 - 1343.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello
Role of Inflammation in Atherosclerosis
J. Nucl. Med., November 1, 2007; 48(11): 1800 - 1815.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. A. Kaufmann, J. M. Sanders, C. Davis, A. Xie, P. Aldred, I. J. Sarembock, and J. R. Lindner
Molecular Imaging of Inflammation in Atherosclerosis With Targeted Ultrasound Detection of Vascular Cell Adhesion Molecule-1
Circulation, July 17, 2007; 116(3): 276 - 284.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
T. Saam, T. S. Hatsukami, N. Takaya, B. Chu, H. Underhill, W. S. Kerwin, J. Cai, M. S. Ferguson, and C. Yuan
The Vulnerable, or High-Risk, Atherosclerotic Plaque: Noninvasive MR Imaging for Characterization and Assessment
Radiology, July 1, 2007; 244(1): 64 - 77.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. M. Greve, A. S. Les, B. T. Tang, M. T. Draney Blomme, N. M. Wilson, R. L. Dalman, N. J. Pelc, and C. A. Taylor
Allometric scaling of wall shear stress from mice to humans: quantification using cine phase-contrast MRI and computational fluid dynamics
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1700 - H1708.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. Maintz, M. Ozgun, A. Hoffmeier, R. Fischbach, W. Y. Kim, M. Stuber, W. J. Manning, W. Heindel, and R. M. Botnar
Selective coronary artery plaque visualization and differentiation by contrast-enhanced inversion prepared MRI
Eur. Heart J., July 2, 2006; 27(14): 1732 - 1736.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
F. Cengelli, D. Maysinger, F. Tschudi-Monnet, X. Montet, C. Corot, A. Petri-Fink, H. Hofmann, and L. Juillerat-Jeanneret
Interaction of Functionalized Superparamagnetic Iron Oxide Nanoparticles with Brain Structures
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 108 - 116.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. A. Trivedi, C. Mallawarachi, J.-M. U-King-Im, M. J. Graves, J. Horsley, M. J. Goddard, A. Brown, L. Wang, P. J. Kirkpatrick, J. Brown, et al.
Identifying Inflamed Carotid Plaques Using In Vivo USPIO-Enhanced MR Imaging to Label Plaque Macrophages
Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1601 - 1606.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
G. Stoll and M. Bendszus
Inflammation and Atherosclerosis: Novel Insights Into Plaque Formation and Destabilization
Stroke, July 1, 2006; 37(7): 1923 - 1932.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. S. Vasan
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Circulation, May 16, 2006; 113(19): 2335 - 2362.
[Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
V. Dousset, B. Brochet, M.S.A. Deloire, L. Lagoarde, B. Barroso, J.-M. Caille, and K.G. Petry
MR Imaging of Relapsing Multiple Sclerosis Patients Using Ultra-Small-Particle Iron Oxide and Compared with Gadolinium.
AJNR Am. J. Neuroradiol., May 1, 2006; 27(5): 1000 - 1005.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. L. Wilensky, H. K. Song, and V. A. Ferrari
Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques.
J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C48 - C56.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. A. Wickline, A. M. Neubauer, P. Winter, S. Caruthers, and G. Lanza
Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology
Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 435 - 441.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. Hyafil, J.-P. Laissy, M. Mazighi, D. Tchetche, L. Louedec, H. Adle-Biassette, S. Chillon, D. Henin, M.-P. Jacob, D. Letourneur, et al.
Ferumoxtran-10-Enhanced MRI of the Hypercholesterolemic Rabbit Aorta: Relationship Between Signal Loss and Macrophage Infiltration
Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 176 - 181.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. M. Moghimi, A. C. Hunter, and J. C. Murray
Nanomedicine: current status and future prospects
FASEB J, March 1, 2005; 19(3): 311 - 330.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
A. M. Lutz, D. Weishaupt, E. Persohn, K. Goepfert, J. Froehlich, B. Sasse, J. Gottschalk, B. Marincek, and A. H. Kaim
Imaging of Macrophages in Soft-Tissue Infection in Rats: Relationship between Ultrasmall Superparamagnetic Iron Oxide Dose and MR Signal Characteristics
Radiology, March 1, 2005; 234(3): 765 - 775.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. E. Sousa, M. A. Costa, E. M. Tuzcu, J. S. Yadav, and S. Ellis
New Frontiers in Interventional Cardiology
Circulation, February 8, 2005; 111(5): 671 - 681.
[Full Text] [PDF]


Home page
Eur Heart JHome page
D. J. Pennell, U. P. Sechtem, C. B. Higgins, W. J. Manning, G. M. Pohost, F. E. Rademakers, A. C. van Rossum, L. J. Shaw, and E. K. Yucel
Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report
Eur. Heart J., November 1, 2004; 25(21): 1940 - 1965.
[Full Text] [PDF]


Home page
RadiologyHome page
A. M. Lutz, C. Seemayer, C. Corot, R. E. Gay, K. Goepfert, B. A. Michel, B. Marincek, S. Gay, and D. Weishaupt
Detection of Synovial Macrophages in an Experimental Rabbit Model of Antigen-induced Arthritis: Ultrasmall Superparamagnetic Iron Oxide-enhanced MR Imaging
Radiology, October 1, 2004; 233(1): 149 - 157.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. A. Trivedi, J.-M. U-King-Im, M. J. Graves, J. J. Cross, J. Horsley, M. J. Goddard, J. N. Skepper, G. Quartey, E. Warburton, I. Joubert, et al.
In Vivo Detection of Macrophages in Human Carotid Atheroma: Temporal Dependence of Ultrasmall Superparamagnetic Particles of Iron Oxide-Enhanced MRI
Stroke, July 1, 2004; 35(7): 1631 - 1635.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. T. Willerson and P. M. Ridker
Inflammation as a Cardiovascular Risk Factor
Circulation, June 1, 2004; 109(21_suppl_1): II-2 - II-10.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. A. Jaffer and R. Weissleder
Seeing Within: Molecular Imaging of the Cardiovascular System
Circ. Res., March 5, 2004; 94(4): 433 - 445.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Kaul and J. R. Lindner
Visualizing coronary atherosclerosis in vivo: thinking big, imaging small
J. Am. Coll. Cardiol., February 4, 2004; 43(3): 461 - 463.
[Full Text] [PDF]


Home page
CirculationHome page
P. M. Winter, A. M. Morawski, S. D. Caruthers, R. W. Fuhrhop, H. Zhang, T. A. Williams, J. S. Allen, E. K. Lacy, J. D. Robertson, G. M. Lanza, et al.
Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With {alpha}v{beta}3-Integrin-Targeted Nanoparticles
Circulation, November 4, 2003; 108(18): 2270 - 2274.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Naghavi, P. Libby, E. Falk, S. W. Casscells, S. Litovsky, J. Rumberger, J. J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, et al.
From Vulnerable Plaque to Vulnerable Patient: A Call for New Definitions and Risk Assessment Strategies: Part I
Circulation, October 7, 2003; 108(14): 1664 - 1672.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Barkhausen, W. Ebert, C. Heyer, J. F. Debatin, and H.-J. Weinmann
Detection of Atherosclerotic Plaque With Gadofluorine-Enhanced Magnetic Resonance Imaging
Circulation, August 5, 2003; 108(5): 605 - 609.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M.E. Kooi, V.C. Cappendijk, K.B.J.M. Cleutjens, A.G.H. Kessels, P.J.E.H.M. Kitslaar, M. Borgers, P.M. Frederik, M.J.A.P. Daemen, and J.M.A. van Engelshoven
Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging
Circulation, May 20, 2003; 107(19): 2453 - 2458.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
A. H. Kaim, G. Jundt, T. Wischer, T. O'Reilly, J. Frohlich, G. K. von Schulthess, and P. R. Allegrini
Functional-Morphologic MR Imaging with Ultrasmall Superparamagnetic Particles of Iron Oxide in Acute and Chronic Soft-Tissue Infection: Study in Rats
Radiology, April 1, 2003; 227(1): 169 - 174.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. A. Wickline and G. M. Lanza
Nanotechnology for Molecular Imaging and Targeted Therapy
Circulation, March 4, 2003; 107(8): 1092 - 1095.
[Full Text] [PDF]


Home page
CirculationHome page
G. J. Tearney, H. Yabushita, S. L. Houser, H. T. Aretz, I.-K. Jang, K. H. Schlendorf, C. R. Kauffman, M. Shishkov, E. F. Halpern, and B. E. Bouma
Quantification of Macrophage Content in Atherosclerotic Plaques by Optical Coherence Tomography
Circulation, January 7, 2003; 107(1): 113 - 119.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. Orlic, J. M. Hill, and A. E. Arai
Stem Cells for Myocardial Regeneration
Circ. Res., December 13, 2002; 91(12): 1092 - 1102.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Corti, V. Fuster, Z. A. Fayad, S. G. Worthley, G. Helft, D. Smith, J. Weinberger, J. Wentzel, G. Mizsei, M. Mercuri, et al.
Lipid Lowering by Simvastatin Induces Regression of Human Atherosclerotic Lesions: Two Years' Follow-Up by High-Resolution Noninvasive Magnetic Resonance Imaging
Circulation, December 3, 2002; 106(23): 2884 - 2887.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
A. H. Kaim, T. Wischer, T. O'Reilly, G. Jundt, J. Frohlich, G. K. von Schulthess, and P. R. Allegrini
MR Imaging with Ultrasmall Superparamagnetic Iron Oxide Particles in Experimental Soft-Tissue Infections in Rats
Radiology, December 1, 2002; 225(3): 808 - 814.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Z. A. Fayad, V. Fuster, K. Nikolaou, and C. Becker
Computed Tomography and Magnetic Resonance Imaging for Noninvasive Coronary Angiography and Plaque Imaging: Current and Potential Future Concepts
Circulation, October 8, 2002; 106(15): 2026 - 2034.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. P. Choudhury, V. Fuster, J. J. Badimon, E. A. Fisher, and Z. A. Fayad
MRI and Characterization of Atherosclerotic Plaque: Emerging Applications and Molecular Imaging
Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1065 - 1074.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ruehm, S. G.
Right arrow Articles by Debatin, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruehm, S. G.
Right arrow Articles by Debatin, J. F.
Related Collections
Right arrow Cardiovascular imaging agents/Techniques
Right arrow Imaging
Right arrow CT and MRI